BioSpace News Archive

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of data from a prospective, multicenter study, called DECIDE

Everest Medicines (HKEX 1952.HK) announced today that South Korea’s Ministry of Food and Drug Safety (MFDS) has granted Global Innovative product on Fast Track (GIFT) designation to Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN).

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2022, and highlighted recent corporate events.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fourth quarter and fiscal year ended November 30, 2022 and provided a corporate update.

Surgery Partners, Inc. announced the Company will release its fourth quarter 2022 results before the market opens on Wednesday, March 1, 2023, to be followed by a conference call at 8:30 a.m..

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced consolidated financial results for the first quarter of fiscal 2023, ended December 31, 2022.

Minerva Surgical, Inc. announced that it has closed on the sale of 146,627,565 shares of its common stock in a private placement, led by Accelmed Partners, with participation by New Enterprise Associates, at an offering price of $0.2046 per share.

Select Medical Holdings Corporation, will release the financial results for its fourth quarter and full year ended December 31, 2022 on Thursday, February 23, 2023 after the market closes.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced the Company will present a corporate overview and host investor meetings at the SVB Securities Global Biopharma Conference and present on Thursday, February 16, 2023, at 12:00 p.m. ET/9:00 a.m. PT.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2022 after the market closes on Tuesday, February 28, 2023.